Long-term Outcomes in Patients with Retinal Vein Occlusion Treated with Ranibizumab: The RETAIN Study – Corrected Proof

Objective: To determine long-term outcomes of patients with ranibizumab-treated retinal vein occlusion (RVO).Design: Prospective follow-up of a subset of patients from 2 phase 3 trials.Participants: Thirty-four patients with branch RVO (BRVO) and 32 with central RVO (CRVO) who completed the Genentech-sponsored ranibizumab study RVO trials.Methods: Patients seen every month in year 1 and at least every 3 months in year 2 were treated with ranibizumab for intraretinal fluid. Patients requiring injections on consecutive visits were treated with ranibizumab plus scatter photocoagulation.Main Outcome Measures: Mean improvement in best-corrected visual acuity (BCVA) and percentage of patients with edema resolution.Results: With a mean (Read more...)

Full Story →